BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 29373841)

  • 1. Recent advances in siRNA delivery for cancer therapy using smart nanocarriers.
    Zhang P; An K; Duan X; Xu H; Li F; Xu F
    Drug Discov Today; 2018 Apr; 23(4):900-911. PubMed ID: 29373841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-targeting multifunctional nanoparticles for siRNA delivery: recent advances in cancer therapy.
    Ku SH; Kim K; Choi K; Kim SH; Kwon IC
    Adv Healthc Mater; 2014 Aug; 3(8):1182-93. PubMed ID: 24577795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-Acidity-Cleavable Maleic Acid Amide (TACMAA): A Powerful Tool for Designing Smart Nanoparticles To Overcome Delivery Barriers in Cancer Nanomedicine.
    Du JZ; Li HJ; Wang J
    Acc Chem Res; 2018 Nov; 51(11):2848-2856. PubMed ID: 30346728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges.
    Gomes-da-Silva LC; Fonseca NA; Moura V; Pedroso de Lima MC; Simões S; Moreira JN
    Acc Chem Res; 2012 Jul; 45(7):1163-71. PubMed ID: 22568781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chitosan Nanoparticles for SiRNA Delivery In Vitro.
    Ragelle H; Vanvarenberg K; Vandermeulen G; Préat V
    Methods Mol Biol; 2016; 1364():143-50. PubMed ID: 26472448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strategies and advances in nanomedicine for targeted siRNA delivery.
    Nimesh S; Gupta N; Chandra R
    Nanomedicine (Lond); 2011 Jun; 6(4):729-46. PubMed ID: 21718181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potential and advances in RNAi therapy: chemical and structural modifications of siRNA molecules and use of biocompatible nanocarriers.
    Joo MK; Yhee JY; Kim SH; Kim K
    J Control Release; 2014 Nov; 193():113-21. PubMed ID: 24862319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delivering siRNA with Dendrimers: In Vivo Applications.
    Leiro V; Santos SD; Pego AP
    Curr Gene Ther; 2017; 17(2):105-119. PubMed ID: 28494741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The importance of co-delivery of nanoparticle-siRNA and anticancer agents in cancer therapy.
    Khelghati N; Soleimanpour Mokhtarvand J; Mir M; Alemi F; Asemi Z; Sadeghpour A; Maleki M; Samadi Kafil H; Jadidi-Niaragh F; Majidinia M; Yousefi B
    Chem Biol Drug Des; 2021 Apr; 97(4):997-1015. PubMed ID: 33458952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in stimuli responsive nanobiomaterials for cancer therapy.
    Sampathkumar K; Arulkumar S; Ramalingam M
    J Biomed Nanotechnol; 2014 Mar; 10(3):367-82. PubMed ID: 24730233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stimuli-sensitive nanopreparations for combination cancer therapy.
    Jhaveri A; Deshpande P; Torchilin V
    J Control Release; 2014 Sep; 190():352-70. PubMed ID: 24818767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanoparticle-Based Combination Therapy for Cancer Treatment.
    Yhee JY; Son S; Lee H; Kim K
    Curr Pharm Des; 2015; 21(22):3158-66. PubMed ID: 26027570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytoplasm-responsive nanocarriers conjugated with a functional cell-penetrating peptide for systemic siRNA delivery.
    Tanaka K; Kanazawa T; Horiuchi S; Ando T; Sugawara K; Takashima Y; Seta Y; Okada H
    Int J Pharm; 2013 Oct; 455(1-2):40-7. PubMed ID: 23911914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycerol monooleate-based nanocarriers for siRNA delivery in vitro.
    Zhen G; Hinton TM; Muir BW; Shi S; Tizard M; McLean KM; Hartley PG; Gunatillake P
    Mol Pharm; 2012 Sep; 9(9):2450-7. PubMed ID: 22794355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficient tuning of siRNA dose response by combining mixed polymer nanocarriers with simple kinetic modeling.
    Greco CT; Muir VG; Epps TH; Sullivan MO
    Acta Biomater; 2017 Mar; 50():407-416. PubMed ID: 28063990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of integrated cancer nanomedicine in overcoming drug resistance.
    Iyer AK; Singh A; Ganta S; Amiji MM
    Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanomedicine based approaches for the delivery of siRNA in cancer.
    Ozpolat B; Sood AK; Lopez-Berestein G
    J Intern Med; 2010 Jan; 267(1):44-53. PubMed ID: 20059643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent progress in nanomaterials for nucleic acid delivery in cancer immunotherapy.
    Mei Y; Wang R; Jiang W; Bo Y; Zhang T; Yu J; Cheng M; Wu Y; Cheng J; Ma W
    Biomater Sci; 2019 Jun; 7(7):2640-2651. PubMed ID: 31090764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances in galactose-engineered nanocarriers for the site-specific delivery of siRNA and anticancer drugs.
    Jain A; Jain A; Parajuli P; Mishra V; Ghoshal G; Singh B; Shivhare US; Katare OP; Kesharwani P
    Drug Discov Today; 2018 May; 23(5):960-973. PubMed ID: 29129804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemistry and formulations for siRNA therapeutics.
    Gallas A; Alexander C; Davies MC; Puri S; Allen S
    Chem Soc Rev; 2013 Oct; 42(20):7983-97. PubMed ID: 23857524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.